Robust detection of EGFR copy number changes and EGFR variant III: technical aspects and relevance for glioma diagnostics.

Published

Journal Article

Epidermal growth factor receptor (EGFR) is commonly affected in cancer, generally in the form of an increase in DNA copy number and/or as mutation variants [e.g., EGFR variant III (EGFRvIII), an in-frame deletion of exons 2-7]. While detection of EGFR aberrations can be expected to be relevant for glioma patients, such analysis has not yet been implemented in a routine setting, also because feasible and robust assays were lacking. We evaluated multiplex ligation-dependent probe amplification (MLPA) for detection of EGFR amplification and EGFRvIII in DNA of a spectrum of 216 diffuse gliomas. EGFRvIII detection was verified at the protein level by immunohistochemistry and at the RNA level using the conventionally used endpoint RT-PCR as well as a newly developed quantitative RT-PCR. Compared to these techniques, the DNA-based MLPA assay for EGFR/EGFRvIII analysis tested showed 100% sensitivity and specificity. We conclude that MLPA is a robust assay for detection of EGFR/EGFRvIII aberrations. While the exact diagnostic, prognostic and predictive value of such EGFR testing remains to be seen, MLPA has great potential as it can reliably and relatively easily be performed on routinely processed (formalin-fixed, paraffin-embedded) tumor tissue in combination with testing for other relevant glioma markers.

Full Text

Duke Authors

Cited Authors

  • Jeuken, J; Sijben, A; Alenda, C; Rijntjes, J; Dekkers, M; Boots-Sprenger, S; McLendon, R; Wesseling, P

Published Date

  • October 2009

Published In

Volume / Issue

  • 19 / 4

Start / End Page

  • 661 - 671

PubMed ID

  • 19744038

Pubmed Central ID

  • 19744038

Electronic International Standard Serial Number (EISSN)

  • 1750-3639

International Standard Serial Number (ISSN)

  • 1015-6305

Digital Object Identifier (DOI)

  • 10.1111/j.1750-3639.2009.00320.x

Language

  • eng